MX391725B - Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. - Google Patents

Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.

Info

Publication number
MX391725B
MX391725B MX2018012655A MX2018012655A MX391725B MX 391725 B MX391725 B MX 391725B MX 2018012655 A MX2018012655 A MX 2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A MX 391725 B MX391725 B MX 391725B
Authority
MX
Mexico
Prior art keywords
compounds
treatment
methods
neurological
cardiovascular conditions
Prior art date
Application number
MX2018012655A
Other languages
English (en)
Spanish (es)
Other versions
MX2018012655A (es
Inventor
James D Lechleiter
Kenneth A Jacobson
Theodore E Liston
William S Korinek
Original Assignee
Astrocyte Pharmaceuticals Inc
Univ Texas
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrocyte Pharmaceuticals Inc, Univ Texas, Us Health filed Critical Astrocyte Pharmaceuticals Inc
Publication of MX2018012655A publication Critical patent/MX2018012655A/es
Publication of MX391725B publication Critical patent/MX391725B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018012655A 2016-04-21 2017-04-21 Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. MX391725B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325860P 2016-04-21 2016-04-21
PCT/US2017/028996 WO2017185061A1 (en) 2016-04-21 2017-04-21 Compounds and methods for treating neurological and cardiovascular conditions

Publications (2)

Publication Number Publication Date
MX2018012655A MX2018012655A (es) 2019-09-06
MX391725B true MX391725B (es) 2025-03-21

Family

ID=60022855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012655A MX391725B (es) 2016-04-21 2017-04-21 Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.

Country Status (12)

Country Link
US (7) US12239654B2 (enExample)
EP (2) EP3445368B1 (enExample)
JP (3) JP7109005B2 (enExample)
KR (2) KR20220132042A (enExample)
CN (2) CN109310695B (enExample)
AU (2) AU2017254720B2 (enExample)
CA (1) CA3020490A1 (enExample)
EA (1) EA201892008A1 (enExample)
ES (1) ES2989621T3 (enExample)
IL (2) IL289423B2 (enExample)
MX (1) MX391725B (enExample)
WO (1) WO2017185061A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120628C2 (uk) 2014-11-07 2020-01-10 Басф Се Пестицидні суміші
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
CA3015456C (en) 2016-03-16 2024-09-17 Basf Se USE OF TETRAZOLINONES TO CONTROL RESISTANT PLANT PATHOGENIC FUNGI ON FRUIT
ES3056157T3 (en) 2016-03-16 2026-02-18 Basf Se Use of a specific tetrazolinone for combating resistant phytopathogenic fungi on cereals
EP3445368B1 (en) 2016-04-21 2024-07-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
CN112218638A (zh) * 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法
WO2019232554A2 (en) * 2018-05-26 2019-12-05 Primetime Life Sciences, Llc Compounds and methods for modulation of g-protein-coupled receptors
WO2020061211A1 (en) * 2018-09-18 2020-03-26 Saint Louis University Use of highly-selective adenosine 3a receptor subtype agonists
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
JP7282324B2 (ja) * 2018-12-11 2023-05-29 株式会社島津製作所 イオン化装置、質量分析装置および流体試料の分析方法
WO2020176544A1 (en) * 2019-02-25 2020-09-03 Saint Louis University Treatment of alzheimer's disease
JOP20210296A1 (ar) * 2019-05-06 2023-01-30 Ferrer Int صور جرعة صلبة صيدلية أو دوائية مغذية متعددة الطبقات ومشتملة على مشتقات بيريميدين و/أو بيورين وفيتامينات ب، وتحضيرها واستخداماتها
IL307967A (en) * 2021-04-28 2023-12-01 Astrocyte Pharmaceuticals Inc Purine nucleosides, their intermediates and methods for their preparation
KR20240122782A (ko) * 2021-11-22 2024-08-13 아스트로사이트 파마슈티컬스, 인코포레이티드 신경학적 및 심혈관 상태를 치료하는 방법
CA3250090A1 (en) * 2022-02-10 2023-08-17 Academia Sinica METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION
WO2024097387A1 (en) * 2022-11-03 2024-05-10 Astrocyte Pharmaceuticals, Inc. Compositions for intravenous administration
WO2024144874A2 (en) * 2022-11-03 2024-07-04 Astrocyte Pharmaceuticals, Inc. Fast-dissolving dosage forms and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002604A1 (en) 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7087589B2 (en) 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
US7589075B2 (en) 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
WO2003051881A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
GB0209539D0 (en) 2002-04-26 2002-06-05 Avecia Ltd Monomer Polymer and process
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
JP2007517019A (ja) * 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
JP2008512457A (ja) 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
EP2049127B1 (en) 2006-05-23 2014-11-26 University of Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2008021552A2 (en) 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20100047798A1 (en) 2006-11-08 2010-02-25 Thomas Jefferson University Adenosine a1 and a3 receptor gene sequence variations for predicting disease outcome and treatment outcome
US7867983B2 (en) 2007-03-29 2011-01-11 The University Of Connecticut Methods to protect skeletal muscle against injury
US20090088403A1 (en) 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
DE102007055529A1 (de) 2007-08-06 2009-02-12 Rhode & Schwarz Gmbh & Co. Kg Verfahren und Anordnung zum Erzeugen eines frequenzmodulierten Signals
JP5592262B2 (ja) 2007-10-15 2014-09-17 キャン−ファイト・バイオファーマ・リミテッド 肝細胞の増殖を誘導する方法及びその使用
BRPI0818578A2 (pt) 2007-10-17 2015-07-21 Novartis Ag Derivados de purina como ligantes receptores de adenosina a1
CN101925610A (zh) 2007-11-23 2010-12-22 巴尔-伊兰大学 不可水解的二磷酸核苷或三磷酸核苷衍生物及其用途
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
EP2331542B1 (en) 2008-08-01 2016-07-27 The United States of America, as Represented by The Secretary, Department of Health and Human Services A3 adenosine receptor antagonists and partial agonists
US8685372B2 (en) 2009-04-15 2014-04-01 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
US8518957B2 (en) 2009-12-02 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
US8822434B2 (en) 2010-02-22 2014-09-02 The University Of Connecticut Compositions and methods to treat cardiac diseases
US8691775B2 (en) 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
SI2968385T1 (sl) 2013-03-13 2018-10-30 Tufts University Uridin nukleozid derivati, sestavki in metode uporabe
US20150087613A1 (en) 2013-09-26 2015-03-26 Saint Louis University Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy
US9963450B2 (en) 2013-11-27 2018-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US20160024135A1 (en) 2014-07-27 2016-01-28 Zhejiang Subtropical Crops Research Institute Adenosine receptor activation reagent and the uses of thereof
HK1247119A1 (zh) 2015-02-04 2018-09-21 贝克心脏与糖尿病研究所 一种治疗方法和用於所述治疗方法中的化合物
RU2017129539A (ru) 2015-02-24 2019-03-25 Гальвани Байоэлектроникс Лимитед Устройство нейромодуляции
CN108685935B (zh) * 2015-05-06 2019-10-11 浙江省亚热带作物研究所 一种含有腺苷受体激动试剂的食品
EP3445368B1 (en) 2016-04-21 2024-07-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
US10683292B2 (en) 2016-07-25 2020-06-16 Nerviano Medical Sciences S.R.L. Purine and 3-deazapurine analogues as choline kinase inhibitors
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
CN112218638A (zh) 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法
KR102602990B1 (ko) 2018-06-27 2023-11-17 에스케이하이닉스 주식회사 전원 공급 장치 및 이를 포함하는 전자 장치
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
IL307967A (en) 2021-04-28 2023-12-01 Astrocyte Pharmaceuticals Inc Purine nucleosides, their intermediates and methods for their preparation
KR20240122782A (ko) 2021-11-22 2024-08-13 아스트로사이트 파마슈티컬스, 인코포레이티드 신경학적 및 심혈관 상태를 치료하는 방법

Also Published As

Publication number Publication date
JP7109005B2 (ja) 2022-07-29
KR20190006501A (ko) 2019-01-18
EP4414027A2 (en) 2024-08-14
US20220000899A1 (en) 2022-01-06
IL289423B1 (en) 2025-11-01
IL262487B (en) 2022-02-01
MX2018012655A (es) 2019-09-06
EP3445368A4 (en) 2019-12-18
IL289423B2 (en) 2026-03-01
ES2989621T3 (es) 2024-11-27
AU2017254720A1 (en) 2018-11-01
BR112018071560A2 (pt) 2019-02-12
WO2017185061A1 (en) 2017-10-26
KR20220132042A (ko) 2022-09-29
IL289423A (en) 2022-02-01
US20180021363A1 (en) 2018-01-25
JP2022088642A (ja) 2022-06-14
US20250345353A1 (en) 2025-11-13
US10953031B2 (en) 2021-03-23
AU2023202694B2 (en) 2025-07-10
EP4414027A3 (en) 2024-11-13
US12239654B2 (en) 2025-03-04
EP3445368B1 (en) 2024-07-17
JP2025084908A (ja) 2025-06-03
EP3445368A1 (en) 2019-02-27
AU2017254720B2 (en) 2023-02-02
CN109310695B (zh) 2022-04-01
JP7709141B2 (ja) 2025-07-16
EP3445368C0 (en) 2024-07-17
US20200046751A1 (en) 2020-02-13
US11484545B2 (en) 2022-11-01
CN109310695A (zh) 2019-02-05
CA3020490A1 (en) 2017-10-26
CN114903903A (zh) 2022-08-16
US20230165887A1 (en) 2023-06-01
NZ747047A (en) 2025-02-28
US10265338B2 (en) 2019-04-23
IL262487A (en) 2018-12-31
KR102445887B1 (ko) 2022-09-21
JP2019515920A (ja) 2019-06-13
US20220305044A1 (en) 2022-09-29
US12390483B2 (en) 2025-08-19
EA201892008A1 (ru) 2019-06-28
US9789131B1 (en) 2017-10-17
AU2023202694A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
MX391725B (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
UY37018A (es) Inhibidores bicíclicos de pad4
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2020006385A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos que comprenden una demencia.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
UY37017A (es) Inhibidores aza-bencimidazol de pad4
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX376201B (es) Compuestos inhibidores de metaloenzima.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2021003515A (es) Compuestos polimorficos y usos de los mismos.
EP3630102C0 (en) FORMULATIONS FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER
BR112017007472A2 (pt) 2-amino-3-fluoro-3-(fluoro metil)-6-metil-6-fenil- 3,4,5,6-tetra-hidropiridinas como inibidores de bace1
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
EP3655036C0 (en) COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS
UA117779C2 (uk) Піразини як модулятори gpr6
PH12016501393B1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX379776B (es) Derivados de diamino piridina para usarse en el tratamiento de dermatitis atópica o psoriasis.
BR112018012343A2 (pt) composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos